JP Morgan Week 2025 – Marianne De Backer
At JPM 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer.
Newsletters and Deep Dive digital magazine
At JPM 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer.
Screening and early detection, as well as the introduction of a human papillomavirus (HPV) vaccine, have fuelled transformative strides in decreasing the burden of cervical cancer for women
While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer recurrence, more effective disease maintenance strategies, more preci
Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.
AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.
Editor's Picks
Newsletters and Deep Dive
digital magazine